SEC Form 4 · accession 0001708138-17-000007
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Terifay
Officer — EVP Commercial
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2017 | M | 48,750 | $52.03 | A | 72,043 | D | |
| Common Stock | Jun 15, 2017 | F | 5,411 | $468.69 | D | 66,632 | D | |
| Common Stock | Jun 15, 2017 | F | 22,192 | $468.69 | D | 44,440 | D | |
| Common Stock | Jun 16, 2017 | S | 21,147 | $468.19 | D | 23,293 | D | |
| Common Stock | holding | — | — | — | 1,699 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $52.03 | Jun 15, 2017 | M | 48,750 | D | — | Dec 16, 2021 | Common Stock | 48,750 | 30,579 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.